243 related articles for article (PubMed ID: 31982622)
1. Evaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis.
Bienvenu AL; Pradat P; Guerin C; Aubrun F; Fellahi JL; Friggeri A; Guichon C; Hernu R; Menotti J; Monard C; Paulus S; Rimmele T; Piriou V; Chidiac C; Argaud L; Leboucher G
Int J Infect Dis; 2020 Apr; 93():15-21. PubMed ID: 31982622
[TBL] [Abstract][Full Text] [Related]
2. Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study.
Garnacho-Montero J; Díaz-Martín A; Cantón-Bulnes L; Ramírez P; Sierra R; Arias-Verdú D; Rodríguez-Delgado M; Loza-Vázquez A; Rodriguez-Gomez J; Gordón M; Estella Á; García-Garmendia JL
Crit Care Med; 2018 Mar; 46(3):384-393. PubMed ID: 29189345
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
5. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis.
Cuervo G; Garcia-Vidal C; Puig-Asensio M; Vena A; Meije Y; Fernández-Ruiz M; González-Barberá E; Blanco-Vidal MJ; Manzur A; Cardozo C; Gudiol C; Montejo JM; Pemán J; Ayats J; Aguado JM; Muñoz P; Marco F; Almirante B; Carratalà J;
Clin Infect Dis; 2017 May; 64(10):1374-1379. PubMed ID: 28329281
[TBL] [Abstract][Full Text] [Related]
6. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort.
López-Cortés LE; Almirante B; Cuenca-Estrella M; Garnacho-Montero J; Padilla B; Puig-Asensio M; Ruiz-Camps I; Rodríguez-Baño J;
Clin Microbiol Infect; 2016 Aug; 22(8):733.e1-8. PubMed ID: 27189197
[TBL] [Abstract][Full Text] [Related]
7. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.
Heimann SM; Cornely OA; Wisplinghoff H; Kochanek M; Stippel D; Padosch SA; Langebartels G; Reuter H; Reiner M; Vierzig A; Seifert H; Vehreschild MJ; Glossmann J; Franke B; Vehreschild JJ
Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):331-8. PubMed ID: 25213718
[TBL] [Abstract][Full Text] [Related]
8. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
9. Initial antifungal strategy does not correlate with mortality in patients with candidemia.
Murri R; Scoppettuolo G; Ventura G; Fabbiani M; Giovannenze F; Taccari F; Milozzi E; Posteraro B; Sanguinetti M; Cauda R; Fantoni M
Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):187-93. PubMed ID: 26634352
[TBL] [Abstract][Full Text] [Related]
10. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.
Eschenauer GA; Carver PL; Lin SW; Klinker KP; Chen YC; Potoski BA; Shields RK; Clancy CJ; Nguyen MH; Lam SW
J Antimicrob Chemother; 2013 Apr; 68(4):922-6. PubMed ID: 23212115
[TBL] [Abstract][Full Text] [Related]
11. Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital.
Girão E; Levin AS; Basso M; Gobara S; Gomes LB; Medeiros EA; Costa SF
Med Mycol; 2008 Sep; 46(6):581-8. PubMed ID: 19180727
[TBL] [Abstract][Full Text] [Related]
12. Impact of biofilm production by Candida species and antifungal therapy on mortality of patients with candidemia.
Lee CH; Chen YC; Chen IL; Chen FJ; Chien CC
Mycoses; 2020 Dec; 63(12):1382-1391. PubMed ID: 32910518
[TBL] [Abstract][Full Text] [Related]
13. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
Kett DH; Shorr AF; Reboli AC; Reisman AL; Biswas P; Schlamm HT
Crit Care; 2011; 15(5):R253. PubMed ID: 22026929
[TBL] [Abstract][Full Text] [Related]
14. Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.
Puig-Asensio M; Fernández-Ruiz M; Aguado JM; Merino P; Lora-Pablos D; Guinea J; Martín-Dávila P; Cuenca-Estrella M; Almirante B
Antimicrob Agents Chemother; 2016 Jun; 60(6):3291-300. PubMed ID: 26976872
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis.
Lin KY; Chen PY; Chuang YC; Wang JT; Sun HY; Sheng WH; Chen YC; Chang SC
J Infect; 2018 Sep; 77(3):242-248. PubMed ID: 29932963
[TBL] [Abstract][Full Text] [Related]
16. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
[TBL] [Abstract][Full Text] [Related]
17. Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?
Le A; Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584138
[TBL] [Abstract][Full Text] [Related]
18. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU.
Nolla-Salas J; Sitges-Serra A; León-Gil C; Martínez-González J; León-Regidor MA; Ibáñez-Lucía P; Torres-Rodríguez JM
Intensive Care Med; 1997 Jan; 23(1):23-30. PubMed ID: 9037636
[TBL] [Abstract][Full Text] [Related]
19. Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia.
Eschenauer GA; Nguyen MH; Clancy CJ
Ann Pharmacother; 2015 Sep; 49(9):1068-74. PubMed ID: 26104051
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period.
Colombo AL; Guimarães T; Sukienik T; Pasqualotto AC; Andreotti R; Queiroz-Telles F; Nouér SA; Nucci M
Intensive Care Med; 2014 Oct; 40(10):1489-98. PubMed ID: 25082359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
